J Korean Child Neurol Soc.  2008 May;16(1):62-70.

Clinical Study of Treatment of Group B Streptococcal Meningitis in Neonates

Affiliations
  • 1Department of Pediatrics, Chonnam National University School of Medicine, Gwangu, Korea. blueixyan@hanmail.net

Abstract

PURPOSE: Penicillin or ampicillin with aminoglycoside is the drug of choice for Group B streptococcal(GBS) meningitis in neonates. Some GBS meningitis, however, does not respond well to the treatment. The purpose of this study was to evaluate the efficacy of early penicillin treatment for the GBS meningitis in neonates.
METHODS
Nineteen cases of GBS meningitis which was proven by CSF culture(13 cases) or latex agglutination test(17 cases) from 1999 to 2007 were retrospectively reviewed. In all cases 3rd-generation cephalosporin was initially given with ampicillin or aminoglycoside. Penicillin was added on the initial regimen according to the CSF results. Seven cases with penicillin given within 3 days of admission(early group) were clinically compared to the other cases(late or non-penicillin group).
RESULTS
Fever continued for 3 to 23 days in the early penicillin group, for 2 to 23 days in the late penicillin group, and persisted in the non-penicillin group. Time needed for negative conversion of CSF bactigen or culture, however, revealed no statistical differences in those 3 groups. Vancomycin was effective in cases with poor responses to other antibiotics.
CONCLUSION
Early penicillin treatment in combination with other antibiotics seemed to shorten the fever duration in the neonatal GBS meningitis.

Keyword

Group B streptococcus; Meningitis; Penicillin

MeSH Terms

Agglutination
Ampicillin
Anti-Bacterial Agents
Fever
Humans
Infant, Newborn
Latex
Meningitis
Penicillins
Retrospective Studies
Vancomycin
Ampicillin
Anti-Bacterial Agents
Latex
Penicillins
Vancomycin
Full Text Links
  • JKCNS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr